Back to search

Netherlands· NL-9178e85436b4

Olmesartan medoxomil Jubilant 10 mg, filmomhulde tabletten

A olmesartan medoxomil product containing olmesartanmedoxomil, registered in Netherlands by Jubilant Pharmaceuticals N.V.. The same ATC class is registered in 15 of our 19 countries.

ATC C09CA08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOlmesartan medoxomil Jubilant 10 mg, …ATCC09CA08REGISTER NO.NL-9178e85436b4PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Olmesartan medoxomil is registered in 15 of 19 countries.

Countries holding a registration under ATC C09CA08 (olmesartan medoxomil), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Olmesartan medoxomil · ATC C09CA08

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of olmesartan medoxomil costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.33 in Italy to $0.86 in Switzerland — a ×2.6 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Olmesartan medoxomil · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.86
  • ES Spain$0.41
  • IT Italy$0.33
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
OLMESARTANMEDOXOMIL
Manufacturer
Jubilant Pharmaceuticals N.V.
Country
Netherlands (NL)
ATC code
C09CA08
ATC class
Olmesartan medoxomil
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    115532

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

216 interactions on record for olmesartan medoxomil.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Olmesartan medoxomil · interactions on record

216 records

  • 7 severe
  • 128 moderate

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium gluconateA12BA05severe
  • Potassium chlorideB05XA01severe

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c3cc6c4f-de2a-44ed-9643-01304a142a5b
GET /v1/drugs/c3cc6c4f-de2a-44ed-9643-01304a142a5b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h115532_smpc.pdf",
  "strength": null,
  "atc_label": "Olmesartan Medoxomil",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg115532",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "OLMESARTANMEDOXOMIL"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h115532.pdf",
  "authorised_at": "2015/08/26",
  "procedure_number": "NL/H/3188/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "115532",
  "additional_monitoring": "N"
}

See everything about olmesartan medoxomil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.